Brief: Denali Therapeutics Q2 EPS USD -0.59
01/08/2024 11:45
Aug 01 (Reuters) - Denali Therapeutics Q2 net income USD -99.026 million. * Q2 basic EPS USD -0.59 * Q2 operating expenses USD 116.593 million * Q2 operating income USD -116.593 million
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers